EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pharmacokinetic modelling of intravenous immunoglobulin in children with primary immunodeficiencies and secondary antibody deficiencies

Iek Leng Cheng iD, Zhong Hui Huang, Austen Worth, Claire Booth, Joseph F Standing iD

British Journal of Clinical Pharmacology · 2026

DOI: 10.1002/bcp.70420 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Iek Leng Cheng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Infection, Immunity and Inflammation Research & Teaching Department, UCL GOS Institute of Child Health, University of London, London, UK. Hauptthemen laut MEDLINE: Immunoglobulins, Intravenous, Models, Biological, Immunologic Deficiency Syndromes, Primary Immunodeficiency Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Education England (HEE)/NIHR.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Children with primary immunodeficiency (PID) and secondary antibody deficiency (SAD) often require immunoglobulin replacement therapy due to low plasma immunoglobulin G (IgG) levels and recurrent infections. Existing pharmacokinetic models for immunoglobulin in PID patients predominantly focus on adults, with limited attention to secondary antibody deficiencies and a lesser emphasis on paediatric populations. This study aims to investigate the pharmacokinetic properties of IgG in paediatric patients with PID and SAD.

Methods

Population pharmacokinetic analysis for PID and SAD children treated with intravenous immunoglobulin at a tertiary paediatric centre was conducted using NONMEM® (7.5.1). Dosing simulations to achieve therapeutic levels of 6 and 8 gL −1 were performed.

Results

A population pharmacokinetic analysis of 64 patients (median age 4.08 years, range 0.06–16.8) was performed. A two‐compartment model with first‐order elimination, incorporating both additive and proportional residual error, adequately described the data. Interindividual variability was modelled on clearance, volume of distribution and baseline IgG levels, with allometric scaling to a 70‐kg body weight applied a priori. The estimated clearance was 0.308 L −1 day −1 70 kg −1 (95% CI 0.23, 0.67), and the volume of distribution was 10.96 L −1 70 kg −1 (95% CI 5.97, 15.79). Patients with SAD exhibited a lower clearance rate of 54% compared with PID patients. Dosing simulations indicated that the recommended SAD dosing regimen maintained therapeutic IgG levels in the simulated population. However, only 44.8% to 51.9% of patients with PID achieved target IgG levels with the standard regimen.

Conclusions

This study provides insights into immunoglobulin pharmacokinetics in paediatric PID and SAD patients, guiding optimised dosing strategies. Administering a loading dose would improve the probability of maintaining therapeutic IgG levels during the 4‐week dosing interval.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunoglobulins, IntravenousModels, BiologicalImmunologic Deficiency SyndromesPrimary Immunodeficiency DiseasesHumansChildChild, PreschoolMaleFemaleAdolescentInfantImmunoglobulin G

Stichwörter der Autor:innen

childrenchimeric antigen receptor T cell therapyimmunoglobulinpharmacokinetic modellingprimary immunodeficiencyrituximabsecondary antibody deficiency

Substanzen

Immunoglobulins, IntravenousImmunoglobulin G

Autor:innen und Institutionen

  • Infection, Immunity and Inflammation Research & Teaching Department, UCL GOS Institute of Child Health, University of London, London, UK.
  • Pharmacy Department, Great Ormond Street Hospital, London, Greater London, UK.
  • Immunology Department, Great Ormond Street Hospital, London, Greater London, UK.

ORCID-Profile: Iek Leng Cheng, Joseph F Standing

Förderung

  • Health Education England (HEE)/NIHR

Zitieren

APA

Cheng, I. L., Huang, Z. H., Worth, A., Booth, C., & Standing, J. F. (2026). Pharmacokinetic modelling of intravenous immunoglobulin in children with primary immunodeficiencies and secondary antibody deficiencies. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70420

Vancouver

Cheng IL, Huang ZH, Worth A, Booth C, Standing JF. Pharmacokinetic modelling of intravenous immunoglobulin in children with primary immunodeficiencies and secondary antibody deficiencies. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70420

BibTeX
@article{Cheng2026,
  author = {Cheng, Iek Leng and Huang, Zhong Hui and Worth, Austen and Booth, Claire and Standing, Joseph F},
  title = {Pharmacokinetic modelling of intravenous immunoglobulin in children with primary immunodeficiencies and secondary antibody deficiencies},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/bcp.70420}
}
Kostenlos starten →